HAVCR2 and neoplasm: Ngiow SF, et al. [30] reported that anti-Tim-3 alone reduced the frequency of Tim-3+ T cells in the TILs of CT26 and MC38 tumor models, and suggested that combination of anti-Tim-3 with anti-CTLA-4 and anti-PD-1 might be well tolerated and very effective.